Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)

NCT06303505 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT06303505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06303505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 12, 2024
Completion date
December 31, 2027
Enrollment
250 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, ovarian cancer